Anixa Biosciences

ANIXAnixa Biosciences

About Anixa Biosciences

Anixa Biosciences (NASDAQ:ANIX) is a biotechnology firm focused on harnessing the body's immune system to fight cancer. Dedicated to developing a range of innovative treatments and vaccines, Anixa's operations span from early research to clinical trials. The company is especially known for its work in developing a cancer vaccine technology aimed at preventing breast cancer, as well as chimeric endocrine receptor T-cell (CER-T) technology targeting prostate cancer. With a commitment to advancing healthcare, Anixa's objectives include bringing groundbreaking immunotherapies and vaccines to market, offering new hope in the fight against cancer.

What is ANIX known for?

Snapshot

Public US

Ownership

1982

Year founded

Employees

San Jose, United States

Head office

Loading Map...

Operations

All Locations

San Jose, US

Products and/or services of Anixa Biosciences

Breast cancer vaccine development focused on preventing the recurrence and development of triple-negative breast cancer, utilizing immunotherapy approaches.
Ovarian cancer vaccine, leveraging the same technology platform as the breast cancer vaccine for prevention and inhibitory growth of ovarian tumors.
CAR-T technology for solid tumors, innovating cellular therapy to target and destroy cancer cells in various solid tumor types.
Cchek™, a proprietary AI-based platform for early cancer detection, using machine learning to analyze simple blood tests for multiple cancer types.
Prostate cancer therapy, focusing on a novel approach to treat early-stage prostate cancer non-invasively, aiming to reduce side effects associated with current treatments.
Collaboration with Cleveland Clinic on developing vaccines, reflecting a strategic partnership to advance prevention therapies for various cancers.